Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Valerie A. Clausen"'
Publikováno v:
Bioanalysis.
Background: Measurement of plasma oxalate (POx) is challenging, but critical, for management of patients with primary hyperoxaluria type 1. A novel LC–MS/MS assay was developed, validated and used to quantify POx in patients with primary hyperoxalu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f4220d067607acd58b7d07dd1b9e6c9
https://doi.org/10.4155/bio-2022-0227
https://doi.org/10.4155/bio-2022-0227
Autor:
Howard A. Burris, Jared A. Gollob, Dinah W.Y. Sah, Akshay K. Vaishnaw, Christina Gamba-Vitalo, Saraswathy V. Nochur, Jeffrey Cehelsky, Valerie A. Clausen, Renta M. Hutabarat, Nenad Svrzikapa, Gregory Hinkle, Rachel E. Meyers, David Bumcrot, Iva Toudjarska, Amy C. Seila White, Jamie Harrop, Rick Falzone, Mrinal M. Gounder, Maria Alsina, Jeffrey R. Infante, Daniel C. Cho, Luis Paz-Ares, Glen J. Weiss, Gary K. Schwartz, Andres Cervantes, Patricia M. LoRusso, Geoffrey I. Shapiro, Josep Tabernero
Supplementary Figures PDF file - 114K, Includes sequence information on KSP and VEGF siRNAs, murine Hep3B tumor model data with ALN-VSP, ALN-VSP Phase I study design, KSP and VEGF mRNA levels in tumor cell lines and normal liver, and comparison of AL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::798921fa41c39c58506772199a018c15
https://doi.org/10.1158/2159-8290.22530521
https://doi.org/10.1158/2159-8290.22530521
Autor:
Howard A. Burris, Jared A. Gollob, Dinah W.Y. Sah, Akshay K. Vaishnaw, Christina Gamba-Vitalo, Saraswathy V. Nochur, Jeffrey Cehelsky, Valerie A. Clausen, Renta M. Hutabarat, Nenad Svrzikapa, Gregory Hinkle, Rachel E. Meyers, David Bumcrot, Iva Toudjarska, Amy C. Seila White, Jamie Harrop, Rick Falzone, Mrinal M. Gounder, Maria Alsina, Jeffrey R. Infante, Daniel C. Cho, Luis Paz-Ares, Glen J. Weiss, Gary K. Schwartz, Andres Cervantes, Patricia M. LoRusso, Geoffrey I. Shapiro, Josep Tabernero
Supplementary Methods and Legends PDF file - 72K, Includes detailed methods for 5' RACE assay and DCE-MRI scans, as well as figure legends for the six supplementary figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b60fded2d3b851bda5dc56f8308997f4
https://doi.org/10.1158/2159-8290.22530518
https://doi.org/10.1158/2159-8290.22530518
Autor:
Howard A. Burris, Jared A. Gollob, Dinah W.Y. Sah, Akshay K. Vaishnaw, Christina Gamba-Vitalo, Saraswathy V. Nochur, Jeffrey Cehelsky, Valerie A. Clausen, Renta M. Hutabarat, Nenad Svrzikapa, Gregory Hinkle, Rachel E. Meyers, David Bumcrot, Iva Toudjarska, Amy C. Seila White, Jamie Harrop, Rick Falzone, Mrinal M. Gounder, Maria Alsina, Jeffrey R. Infante, Daniel C. Cho, Luis Paz-Ares, Glen J. Weiss, Gary K. Schwartz, Andres Cervantes, Patricia M. LoRusso, Geoffrey I. Shapiro, Josep Tabernero
Supplementary Tables PDF file - 67K, Includes data showing effect of ALN-VSP on spleen in non-human primates, tumor response data from the Phase I trial, and safety data (including adverse events and dose-limiting toxicities) from the Phase I trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2abf232c1a30a2513228f151bdf1bb65
https://doi.org/10.1158/2159-8290.22530515
https://doi.org/10.1158/2159-8290.22530515
Autor:
Li-Hua Guan, Qianfan Wang, Jing Li, Carrie Rocca, Valerie A. Clausen, Saeho Chong, Chris Tran, Yuanxin Xu, Guodong Zhang, Michael Arciprete, Ju Liu, Diana Najarian, Jing-Tao Wu, Xuemei Zhang, Peter F Smith
Publikováno v:
Drug Metabolism and Disposition. 49:572-580
Givosiran is an N-acetylgalactosamine-conjugated RNA interference therapeutic that targets 5'-aminolevulinate synthase 1 mRNA in the liver and is currently marketed for the treatment of acute hepatic porphyria. Herein, nonclinical pharmacokinetics an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::845f7b4ca8072422f3e99326db273257
https://doi.org/10.1124/dmd.121.000381
https://doi.org/10.1124/dmd.121.000381
Autor:
Nader Najafian, Gabriel J. Robbie, Varun Goel, Anna Borodovsky, Prajakta S. Badri, Jae Kim, Bahru A. Habtemariam, Xuemin Jiang, Valerie A. Clausen
Publikováno v:
Clinical Pharmacokinetics. 60:365-378
Cemdisiran, an N-acetylgalactosamine (GalNAc) conjugated RNA interference (RNAi) therapeutic, is currently under development for the treatment of complement-mediated diseases by suppressing liver production of complement 5 (C5) protein. This study wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6932d0b308fda4f80e2b4762ef480b9
https://doi.org/10.1007/s40262-020-00940-9
https://doi.org/10.1007/s40262-020-00940-9
Autor:
Husain Attarwala, Valerie A. Clausen, Pushkal Garg, Varun Goel, Verena Karsten, Gabriel J. Robbie, Megan Melch, Akshay Vaishnaw, Bahru A. Habtemariam, John Vest, Marianne T. Sweetser
Publikováno v:
Clinical Pharmacology & Therapeutics. 109:372-382
Vutrisiran (ALN-TTRsc02) is a liver-directed, investigational, small interfering ribonucleic acid drug for the treatment of transthyretin (TTR)-mediated amyloidosis. This phase I, randomized, single-blind, placebo-controlled, single ascending dose st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a926fdfa0bbe0b749b1e462a6eaad07d
https://doi.org/10.1002/cpt.1974
https://doi.org/10.1002/cpt.1974
Autor:
Gabriel J. Robbie, Amy Simon, Valerie A. Clausen, Varun Goel, Jae B. Kim, Sagar Agarwal, Bahru A. Habtemariam
Publikováno v:
Clinical Pharmacology & Therapeutics. 108:63-72
Givosiran is a small interfering ribonucleic acid agent that was recently approved in the United States for the treatment of acute hepatic porphyria (AHP). This phase I study evaluated the safety, pharmacokinetic, and pharmacodynamic profile of subcu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5b0bab872007ea5a880d07aa98e36af
https://doi.org/10.1002/cpt.1802
https://doi.org/10.1002/cpt.1802
Autor:
Gabriel J. Robbie, Ling Shen, Erik Mogalian, Christopher MacLauchlin, Sneha V. Gupta, Jing Li, Valerie A. Clausen, Daniel Cloutier, Marie Christine Fanget
Publikováno v:
Drugs in R&D
Background and Objective VIR-2218 is an investigational N-acetylgalactosamine–conjugated RNA interference therapeutic in development for chronic hepatitis B virus (HBV) infection. VIR-2218 was designed to silence HBV transcripts across all genotype
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a45929a3f75e16ffd3e8911a939c3b59
https://pubmed.ncbi.nlm.nih.gov/34741731
https://pubmed.ncbi.nlm.nih.gov/34741731
Autor:
Eliane Sardh, Nader Najafian, Sagar Agarwal, Pauline Harper, Valerie A. Clausen, Amy Simon, Gabriel J. Robbie, Daphne Vassiliou
Publikováno v:
Clinical pharmacology and therapeutics. 110(5)
Givosiran (trade name GIVLAARI) is a small interfering ribonucleic acid that targets hepatic delta-aminolevulinic acid synthase 1 (ALAS1) messenger RNA for degradation through RNA interference (RNAi) that has been approved for the treatment of acute
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bda1c1811dd672c7e7c92f4e1b038f3
https://pubmed.ncbi.nlm.nih.gov/34510420
https://pubmed.ncbi.nlm.nih.gov/34510420